Generation Bio Co.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Anthony Quinn. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Anthony Quinn has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:GBIO / Generation Bio Co. Director 299,286
US:AGLE / Aeglea BioTherapeutics Inc President & CEO, Director 550,540
US:KLDO / Kaleido Biosciences, Inc. Director 15,000
US:GEVA / Synageva Biopharma Corp EVP, CMO, & Head of R&D 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Anthony Quinn. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases GBIO / Generation Bio Co. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GBIO / Generation Bio Co.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2025-01-13 GBIO Quinn Anthony 85,000 0.9700 8,500 9.7000 82,450 213 6.6600 -25,840 -31.34
2025-01-10 GBIO Quinn Anthony 125,791 0.9600 12,579 9.6000 120,759
2023-12-01 GBIO Quinn Anthony 88,495 1.4100 8,850 14.1000 124,778

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GBIO / Generation Bio Co. Insider Trades
Insider Sales GBIO / Generation Bio Co. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GBIO / Generation Bio Co.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GBIO / Generation Bio Co. Insider Trades
Insider Purchases KLDO / Kaleido Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GBIO / Generation Bio Co.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KLDO / Kaleido Biosciences, Inc. Insider Trades
Insider Sales KLDO / Kaleido Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GBIO / Generation Bio Co.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KLDO / Kaleido Biosciences, Inc. Insider Trades
Insider Purchases SYRE / Spyre Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in GBIO / Generation Bio Co.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2022-03-16 AGLE Quinn Anthony 80,079 2.3440 3,203 58.6000 187,705 2 68 30,099 16.04
2022-03-15 AGLE Quinn Anthony 42,417 1.8611 1,697 46.5275 78,942
2022-03-14 AGLE Quinn Anthony 67,472 1.9300 2,699 48.2500 130,221
2022-03-11 AGLE Quinn Anthony 34,777 2.0640 1,391 51.6000 71,780
2021-12-10 AGLE Quinn Anthony 10,526 3.7500 421 93.7500 39,472
2021-12-09 AGLE Quinn Anthony 43,108 3.7000 1,724 92.5000 159,500
2020-04-30 AGLE Quinn Anthony 165,000 4.7500 6,600 118.7500 783,750
2019-06-14 AGLE Quinn Anthony 5,282 6.2311 211 155.7775 32,913
2019-06-13 AGLE Quinn Anthony 14,406 6.1666 576 154.1650 88,836
2019-06-12 AGLE Quinn Anthony 12,217 6.1148 489 152.8700 74,705
2019-05-22 AGLE Quinn Anthony 3,809 6.8596 152 171.4900 26,128
2019-05-21 AGLE Quinn Anthony 13,794 6.8857 552 172.1425 94,981
2019-05-20 AGLE Quinn Anthony 8,989 6.5550 360 163.8750 58,923
2019-05-17 AGLE Quinn Anthony 6,218 6.6477 249 166.1925 41,335
2019-05-16 AGLE Quinn Anthony 5,520 6.8280 221 170.7000 37,691
2019-05-15 AGLE Quinn Anthony 6,256 6.7566 250 168.9150 42,269
2019-02-15 AGLE Quinn Anthony 719 7.0980 29 177.4500 5,103
2018-08-15 AGLE Quinn Anthony 994 9.1300 40 228.2500 9,075
2018-02-15 AGLE Quinn Anthony 2,000 6.0200 80 150.5000 12,040
2017-12-08 AGLE Quinn Anthony 600 5.0650 24 126.6250 3,039
2017-12-07 AGLE Quinn Anthony 2,800 4.9882 112 124.7050 13,967
2017-12-06 AGLE Quinn Anthony 4,888 4.9248 196 123.1200 24,072
2017-12-05 AGLE Quinn Anthony 5,065 4.9310 203 123.2750 24,976
2017-12-04 AGLE Quinn Anthony 7,956 4.9804 318 124.5100 39,624
2017-12-01 AGLE Quinn Anthony 4,100 4.5312 164 113.2800 18,578
2016-04-12 AGLE Quinn Anthony 10,000 10.0000 400 250.0000 100,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRE / Spyre Therapeutics, Inc. Insider Trades
Insider Sales SYRE / Spyre Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in GBIO / Generation Bio Co.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRE / Spyre Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Anthony Quinn as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-01-14 2025-01-13 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 85,000 299,286 39.67 0.97 82,450 290,307
2025-01-14 2025-01-10 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 125,791 214,286 142.14 0.96 120,759 205,715
2023-12-05 2023-12-01 4 GBIO Generation Bio Co.
Common Stock
P - Purchase 88,495 88,495 1.41 124,778 124,778
2022-03-18 2022-03-16 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 80,079 550,540 17.02 2.34 187,705 1,290,466
2022-03-15 2022-03-15 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 42,417 473,461 9.84 1.86 78,942 881,158
2022-03-15 2022-03-14 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 67,472 431,044 18.56 1.93 130,221 831,915
2022-03-15 2022-03-11 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 34,777 363,572 10.58 2.06 71,780 750,413
2022-02-22 2022-02-17 4 AGLE Aeglea BioTherapeutics, Inc.
Employee Stock Option (right to buy)
A - Award 350,000 350,000
2022-02-14 2021-10-20 5 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
G - Gift 10,000 208,845 5.03
2022-02-14 2021-10-20 5 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
G - Gift -10,000 328,795 -2.95
2022-02-14 2021-10-18 5 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
G - Gift 23,809 208,845 12.87
2022-02-14 2021-10-18 5 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
G - Gift -23,809 328,795 -6.75
2022-02-14 2021-10-14 5 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
G - Gift 175,036 208,845 517.72
2022-02-14 2021-10-14 5 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
G - Gift -175,036 328,795 -34.74
2022-02-14 2018-12-28 5 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
G - Gift 57,450 57,450
2022-02-14 2018-12-28 5 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
G - Gift -57,450 328,795 -14.87
2021-12-13 2021-12-10 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 10,526 328,795 3.31 3.75 39,472 1,232,981
2021-12-13 2021-12-09 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 43,108 318,269 15.67 3.70 159,500 1,177,595
2021-10-29 2021-10-28 4 GBIO Generation Bio Co.
Common Stock
G - Gift 72,837 72,837
2021-10-29 2021-10-28 4 GBIO Generation Bio Co.
Common Stock
G - Gift -72,837 0 -100.00
2021-07-01 2021-06-30 4 KLDO Kaleido Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2021-06-11 2021-06-09 4 GBIO Generation Bio Co.
Stock Option (right to buy)
A - Award 15,000 15,000
2021-02-19 2021-02-17 4 AGLE Aeglea BioTherapeutics, Inc.
Employee Stock Option (right to buy)
A - Award 330,000 330,000
2020-07-01 2020-06-30 4 KLDO Kaleido Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2020-06-18 2020-06-16 4 GBIO Generation Bio Co.
Series C Preferred Stock
C - Conversion -53,654 0 -100.00
2020-06-18 2020-06-16 4 GBIO Generation Bio Co.
Common Stock
C - Conversion 30,376 72,837 71.54
2020-06-15 2020-06-11 4 GBIO Generation Bio Co.
Stock Option (right to buy)
A - Award 52,000 52,000
2020-06-11 3 GBIO Generation Bio Co.
Common Stock
84,922
2020-06-11 3 GBIO Generation Bio Co.
Common Stock
84,922
2020-06-11 3 GBIO Generation Bio Co.
Common Stock
84,922
2020-05-04 2020-04-30 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 165,000 538,469 44.18 4.75 783,750 2,557,728
2020-02-19 2020-02-14 4 AGLE Aeglea BioTherapeutics, Inc.
Employee Stock Option (right to buy)
A - Award 301,000 301,000
2019-10-07 2019-10-04 4 AGLE Aeglea BioTherapeutics, Inc.
Stock Option (right to buy)
M - Exercise -17,603 119,914 -12.80
2019-10-07 2019-10-04 4 AGLE Aeglea BioTherapeutics, Inc.
Stock Option (right to buy)
M - Exercise -662 0 -100.00
2019-10-07 2019-10-04 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
M - Exercise 17,603 371,908 4.97 6.31 111,075 2,346,739
2019-10-07 2019-10-04 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
M - Exercise 662 354,305 0.19 5.46 3,615 1,934,505
2019-06-14 2019-06-14 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 5,282 353,643 1.52 6.23 32,913 2,203,585
2019-06-14 2019-06-13 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 14,406 348,361 4.31 6.17 88,836 2,148,203
2019-06-14 2019-06-12 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 12,217 333,955 3.80 6.11 74,705 2,042,068
2019-05-22 2019-05-22 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 3,809 321,738 1.20 6.86 26,128 2,206,994
2019-05-22 2019-05-21 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 13,794 317,929 4.54 6.89 94,981 2,189,164
2019-05-22 2019-05-20 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 8,989 304,135 3.05 6.56 58,923 1,993,605
2019-05-17 2019-05-17 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 6,218 295,146 2.15 6.65 41,335 1,962,042
2019-05-17 2019-05-16 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 5,520 288,928 1.95 6.83 37,691 1,972,800
2019-05-17 2019-05-15 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 6,256 283,408 2.26 6.76 42,269 1,914,874
2019-05-17 2019-02-15 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 719 277,152 0.26 7.10 5,103 1,967,225
2019-03-04 2019-03-04 4 KLDO Kaleido Biosciences, Inc.
Series B Preferred Stock
C - Conversion -25,707 0 -100.00
2019-03-04 2019-03-04 4 KLDO Kaleido Biosciences, Inc.
Common Stock
C - Conversion 12,853 31,603 68.55
2019-03-01 2019-02-28 4 AGLE Aeglea BioTherapeutics, Inc.
Stock Option (right to buy)
A - Award 280,000 280,000
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
37,500
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
37,500
2019-02-27 3 KLDO Kaleido Biosciences, Inc.
Common Stock
37,500
2019-02-08 2019-02-06 4 AGLE Aeglea BioTherapeutics, Inc.
Stock Option (right to buy)
M - Exercise -7,433 137,517 -5.13
2019-02-08 2019-02-06 4 AGLE Aeglea BioTherapeutics, Inc.
Stock Option (right to buy)
M - Exercise -1,323 662 -66.65
2019-02-08 2019-02-06 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
M - Exercise 7,433 276,433 2.76 6.31 46,902 1,744,292
2019-02-08 2019-02-06 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
M - Exercise 1,323 269,000 0.49 5.46 7,224 1,468,740
2018-12-10 2018-12-07 4 AGLE Aeglea BioTherapeutics, Inc.
Director Stock Option (right to buy)
M - Exercise -18,584 144,950 -11.36
2018-12-10 2018-12-07 4 AGLE Aeglea BioTherapeutics, Inc.
Director Stock Option (right to buy)
M - Exercise -3,306 1,985 -62.48
2018-12-10 2018-12-07 4 AGLE Aeglea BioTherapeutics, Inc.
Director Stock Option (right to buy)
M - Exercise -150,000 0 -100.00
2018-12-10 2018-12-07 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
M - Exercise 18,584 267,677 7.46 6.31 117,265 1,689,042
2018-12-10 2018-12-07 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
M - Exercise 3,306 249,093 1.35 5.46 18,051 1,360,048
2018-12-10 2018-12-07 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
M - Exercise 150,000 245,787 156.60 4.11 616,500 1,010,185
2018-12-10 2018-08-15 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 994 95,787 1.05 9.13 9,075 874,535
2018-12-10 2018-02-15 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 2,000 94,793 2.16 6.02 12,040 570,654
2018-07-20 2018-07-18 4 AGLE Aeglea BioTherapeutics, Inc.
Employee Stock Option (right to buy)
A - Award 50,000 50,000
2018-07-20 2018-07-18 4 AGLE Aeglea BioTherapeutics, Inc.
Employee Stock Option (right to buy)
A - Award 75,000 75,000
2018-07-20 2018-07-18 4 AGLE Aeglea BioTherapeutics, Inc.
Employee Stock Option (right to buy)
A - Award 75,000 75,000
2018-07-20 2018-07-18 4 AGLE Aeglea BioTherapeutics, Inc.
Employee Stock Option (right to buy)
A - Award 300,000 300,000
2018-07-16 2018-07-12 4 AGLE Aeglea BioTherapeutics, Inc.
Director Stock Option (right to buy)
M - Exercise -14,866 163,534 -8.33
2018-07-16 2018-07-12 4 AGLE Aeglea BioTherapeutics, Inc.
Director Stock Option (right to buy)
M - Exercise -24,000 0 -100.00
2018-07-16 2018-07-12 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
M - Exercise 14,866 92,793 19.08 6.31 93,804 585,524
2018-07-16 2018-07-12 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
M - Exercise 24,000 77,927 44.50 7.04 168,960 548,606
2018-07-13 2018-07-11 4 AGLE Aeglea BioTherapeutics, Inc.
Director Stock Option (right to buy)
M - Exercise -3,307 5,291 -38.46
2018-07-13 2018-07-11 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
M - Exercise 3,307 53,927 6.53 5.46 18,056 294,441
2018-02-22 2018-02-20 4 AGLE Aeglea BioTherapeutics, Inc.
Employee Stock Option (right to buy)
A - Award 178,400 178,400
2018-02-20 2018-02-15 4 AGLE Aeglea BioTherapeutics, Inc.
Director Stock Option (right to buy)
M - Exercise -15,211 8,598 -63.89
2018-02-20 2018-02-15 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
M - Exercise 15,211 50,620 42.96 5.46 83,052 276,385
2017-12-08 2017-12-08 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 600 35,409 1.72 5.06 3,039 179,347
2017-12-08 2017-12-07 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 2,800 34,809 8.75 4.99 13,967 173,634
2017-12-08 2017-12-06 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 4,888 32,009 18.02 4.92 24,072 157,638
2017-12-05 2017-12-05 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 5,065 27,121 22.96 4.93 24,976 133,734
2017-12-05 2017-12-04 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 7,956 22,056 56.43 4.98 39,624 109,848
2017-12-05 2017-12-01 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 4,100 14,100 41.00 4.53 18,578 63,890
2017-09-01 2017-08-31 4 AGLE Aeglea BioTherapeutics, Inc.
Employee Stock Option (right to buy)
A - Award 150,000 150,000
2017-04-25 2017-04-21 4 AGLE Aeglea BioTherapeutics, Inc.
Employee Stock Option (right to buy)
A - Award 24,000 24,000
2016-04-12 2016-04-12 4 AGLE Aeglea BioTherapeutics, Inc.
Common Stock
P - Purchase 10,000 10,000 10.00 100,000 100,000
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -45,000 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -45,000 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -35,000 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -20,497 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -37,228 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -5,982 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -8,964 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
D - Sale to Issuer -27,000 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
D - Sale to Issuer -5,675 27,000 -17.37
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
A - Award 38 32,675 0.12 78.87 2,997 2,577,077
2015-06-09 2015-06-05 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
A - Award 27,000 32,637 478.98
2015-04-29 2015-04-27 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -10,000 37,228 -21.17
2015-04-29 2015-04-27 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -10,000 5,637 -63.95 110.00 -1,100,000 620,070
2015-04-29 2015-04-27 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 10,000 15,637 177.40 1.70 17,000 26,583
2015-04-23 2015-04-21 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -10,000 5,637 -63.95 108.00 -1,080,000 608,796
2015-04-17 2015-04-15 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -10,000 35,000 -22.22
2015-04-17 2015-04-15 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -10,000 15,637 -39.01 105.00 -1,050,000 1,641,885
2015-04-17 2015-04-15 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 10,000 25,637 63.95 40.74 407,400 1,044,451
2015-04-08 2015-04-06 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -9,503 20,497 -31.68
2015-04-08 2015-04-06 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -10,000 8,964 -52.73
2015-04-08 2015-04-06 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -29,503 15,637 -65.36 93.76 -2,766,201 1,466,125
2015-04-08 2015-04-06 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 9,503 45,140 26.67 23.00 218,569 1,038,220
2015-04-08 2015-04-06 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 10,000 35,637 39.01 0.95 9,500 33,855
2015-04-08 2015-04-06 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
A - Award 42 25,637 0.16 76.88 3,229 1,970,973
2014-09-04 2014-09-02 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -10,000 30,000 -25.00
2014-09-04 2014-09-02 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -300 25,595 -1.16 72.88 -21,864 1,865,364
2014-09-04 2014-09-02 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -700 25,895 -2.63 71.96 -50,372 1,863,404
2014-09-04 2014-09-02 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -400 26,595 -1.48 70.50 -28,200 1,874,948
2014-09-04 2014-09-02 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -8,600 26,995 -24.16 69.88 -600,968 1,886,411
2014-09-04 2014-09-02 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 10,000 35,595 39.07 23.00 230,000 818,685
2014-07-02 2014-06-30 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
A - Award 71 25,595 0.28 54.89 3,897 1,404,910
2014-06-05 2014-06-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 45,000 45,000
2014-04-03 2014-04-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -10,000 18,964 -34.53
2014-04-03 2014-04-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 10,000 25,524 64.42 0.95 9,500 24,248
2014-04-03 2014-04-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -10,000 40,000 -20.00
2014-04-03 2014-04-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -10,000 40,000 -20.00
2014-04-03 2014-04-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -1,050 15,524 -6.34 85.76 -90,048 1,331,338
2014-04-03 2014-04-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -4,746 16,574 -22.26 84.72 -402,081 1,404,149
2014-04-03 2014-04-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -3,529 21,320 -14.20 83.50 -294,672 1,780,220
2014-04-03 2014-04-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -10,675 24,849 -30.05 82.80 -883,890 2,057,497
2014-04-03 2014-04-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 10,000 35,524 39.18 23.00 230,000 817,052
2014-04-03 2014-04-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 10,000 25,524 64.42 0.95 9,500 24,248
2014-01-02 2013-12-31 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
A - Award 192 15,524 1.25 36.30 6,970 563,521
2013-07-01 2013-06-28 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
A - Award 297 15,332 1.98 35.68 10,597 547,046
2013-06-10 2013-06-06 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 45,000 45,000
2013-01-23 2013-01-18 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -9,447 38,964 -19.51
2013-01-23 2013-01-18 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -9,447 15,035 -38.59 50.08 -473,106 752,953
2013-01-23 2013-01-18 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 9,447 24,482 62.83 0.95 8,975 23,258
2013-01-18 2013-01-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -200 48,411 -0.41
2013-01-18 2013-01-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -200 15,035 -1.31 50.00 -10,000 751,750
2013-01-18 2013-01-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 200 15,235 1.33 0.95 190 14,473
2013-01-18 2013-01-16 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -353 48,611 -0.72
2013-01-18 2013-01-16 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -5,353 15,035 -26.26 50.07 -268,025 752,802
2013-01-18 2013-01-16 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 353 20,388 1.76 0.95 335 19,369
2012-07-30 2012-07-27 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -6,400 48,964 -11.56
2012-07-30 2012-07-27 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -6,400 20,035 -24.21 50.23 -321,501 1,006,450
2012-07-30 2012-07-27 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 6,400 26,435 31.94 0.95 6,080 25,113
2012-07-30 2012-07-26 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -1,100 55,364 -1.95
2012-07-30 2012-07-26 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -1,100 20,035 -5.20 50.00 -55,000 1,001,750
2012-07-30 2012-07-26 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 1,100 21,135 5.49 0.95 1,045 20,078
2012-07-23 2012-07-20 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -600 56,464 -1.05
2012-07-23 2012-07-20 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -600 20,035 -2.91 50.00 -30,000 1,001,750
2012-07-23 2012-07-20 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 600 20,635 2.99 0.95 570 19,603
2012-07-23 2012-07-19 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -1,900 57,064 -3.22
2012-07-23 2012-07-19 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -1,900 20,035 -8.66 50.00 -95,000 1,001,750
2012-07-23 2012-07-19 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 1,900 21,935 9.48 0.95 1,805 20,838
2012-06-29 2012-06-27 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 45,000 45,000
2012-06-27 2012-06-25 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -26,000 20,035 -56.48 40.65 -1,056,874 814,403
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)